This product is a second-generation cephalosporin for intravenous or intramuscular injection. This product has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.

It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding proteins, which are the usual action points of β-lactam antibiotics. It can inhibit cell wall synthesis and bind to peptidoglycan, inhibiting the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and showing a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of the MIC.

It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding protein, which is the usual point of action of beta-lactam antibiotics, inhibits cell wall synthesis, binds to peptidoglycan, inhibits the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and shows a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of MIC.

This product has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is to show a strong affinity for penicillin-binding protein, which is the usual point of action of beta-lactam antibiotics, inhibit cell wall synthesis, bind to peptidoglycan, inhibit the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and show a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of MIC.

This product belongs to the third generation of cephalosporin, with a broad-spectrum antibacterial effect, and is stable against broad-spectrum beta-lactamases (including penicillinase and cephalosporinase) produced by various Gram-positive and Gram-negative bacteria. This product has a strong antibacterial effect on Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. Pseudomonas and Acinetobacter species such as Pseudomonas aeruginosa are less sensitive to this product. Ceftizoxime has a good antibacterial effect on Haemophilus influenzae and Neisseria gonorrhoeae. This product has a poorer effect on Staphylococcus aureus and Staphylococcus epidermidis than the first and second generation cephalosporins. Methicillin-resistant Staphylococcus aureus and Enterococcus are resistant to this product, and various streptococci are highly sensitive to this product. Anaerobic bacteria such as Peptococcus, Peptostreptococcus and some Bacteroides are mostly sensitive to this product, and Clostridium difficile is resistant to this product. 2. The mechanism of action of this product is to achieve bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides.